A Clinical Trial to Assess the Effect of AP-Brain Collagen Peptides on the Improvement of Attention, Focus, and Memory in Stressed But Otherwise Healthy Individuals

NCT07572240 · tracked via the Priya Life Science India tracker

Sponsor

Rousselot BVBA

Phase

Not applicable

Started

2026-07-27

Last updated

2026-09-21

Condition(s) studied

HealthyStress

Investigational drug(s) / intervention(s)

AP-Brain Collagen Peptide

AP-Brain Collagen Peptide: Single dose once daily

Study summary

The goal of this clinical trial is to learn about the effects of AP-Brain collagen peptide on attention, focus, and memory in adults who are stressed but otherwise healthy.

The main questions it aims to answer are:

* How does AP-Brain affect a participant's attention, focus, stress, and memory?
* Is there a difference in the effects between a higher dose and a lower dose?
* What are the side effects, if any, for participants taking AP-Brain?

Researchers will compare two different doses of AP-Brain to see how they affect brain function and stress levels.

Participants in this study will be asked to:

* Take one of two the doses of AP-Brain once a day for 56 days.
* Visit the study center for regular checkups.
* Complete tasks that measure memory, focus, and attention.
* Answer survey questions about their stress levels.
* Provide blood samples and have vital signs checked.
* Have the brain's response to tasks monitored to see how it affects attention and alertness.

Eligibility

Sex

ALL

Min age

35 Years

Max age

70 Years

Healthy volunteers

Accepted

Inclusion Criteria: * Individuals ready to give voluntary, written informed consent to participate in the study. * Male and female individuals of age between 35 to 70 years (both values included). * Individuals with body mass index (BMI) between 18.5 kg/m\^2 to 29.9 kg/m\^2 (both values included). * Perceived Stress Scale (PSS) scores between 14 to 26 (both values included). * Individuals with mild cognitive impairment as indicated by Addenbrooke's Cognitive Examination (ACE) III scores between 75 to 88 (both values included). * Self-reported mild difficulties in focus, attention, or memory. * Progressive cognitive complaints like stress, disturbed sleep etc. reported by participant. * Individuals willing to consume an investigational product from bovine source. * Individuals willing to complete all study-related and clinical study visits as per protocol. Exclusion Criteria: * Clinically diagnosed with Attention Deficit Hyperactivity Disorder (ADHD). * Clinically diagnosed with mental disorders (diagnostic and statistical manual of mental disorders: DSM-5-TR), namely but not limited to epilepsy, anxiety, depression or Alzheimer's disease. * Individuals with a medical history of cardiac disease, respiratory disorders, kidney disorder, liver disorder, or seizure disorders or other chronic health conditions requiring medication. * Individuals with uncontrolled hypertension (systolic blood pressure greater than or equal to 140 mmHg or diastolic blood pressure greater than or equal to 90 mmHg). * Individuals with uncontrolled diabetes (fasting blood glucose (FBG) greater than equal to 126 mg/dl). * Individuals with history of hypersensitivity to any components of the investigational product. * Those taking prescription medication or dietary supplements that affect cognitive function within 30 days prior to screening. * Head injury immediately preceding cognitive deterioration. * Consumption of excessive amounts of caffeine (more than 4-5 cups per day) and caffeine-containing foods or beverages. * Current smokers. * Those who are deemed unable to comply with the test requirements or otherwise deemed unsuitable according to the Investigator's opinion. * Females who are pregnant/planning to be pregnant/lactating or taking any oral contraceptives. * History of drug or alcohol addiction or abuse with the past 12 months.

Primary outcome measure(s)

Change from Baseline and Different Doses on Selective Attention and Focus by Stroop Color-Word Test at Day 56 — Baseline and Day 56
The Stroop Color Word Test is a validated neuropsychological assessment used to measure selective attention, cognitive flexibility, processing speed, and executive control. The test requires participants to identify the ink color of printed words that may represent incongruent color names, thereby assessing the ability to inhibit automatic responses and manage cognitive interference. The change in selective attention and focus will be measured by change in mean reaction time (ms) and stroop latency by Stroop Color-Word test.

Trial sites (8)

Facility	City	Region
Omkar ENT Hospital and Research Centre	Nashik	Maharashtra
Samarth Hospital	Nashik	Maharashtra
New Manak Healthcare Care Hospital	Navi Mumbai	Maharashtra
Punawale Multispecialty Hospital	Pimpri-Chinchwad	Maharashtra
Bhaktisiddhant Hospital	Pimpri-Chinchwad	Maharashtra
Pawana Hospital	Pune	Maharashtra
Silver Birch Multispecialty Hospital	Pune	Maharashtra
Gurukrupa Hospital	Thane	Maharashtra

Other trials for the same condition

Empowering Adolescents to Lead Change Using Health Data Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07572240 on ClinicalTrials.gov ↗ ← All trials in India